Nuvation Bio (NYSE:NUVB) Given New $7.00 Price Target at UBS Group

Nuvation Bio (NYSE:NUVB) had its price target reduced by UBS Group from $10.00 to $7.00 in a research report released on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

NUVB has been the subject of several other reports. Citizens Jmp set a $10.00 price target on shares of Nuvation Bio in a research report on Thursday, November 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research note on Thursday, January 22nd. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Nuvation Bio in a research report on Tuesday, February 10th. Truist Financial set a $13.00 price target on Nuvation Bio in a report on Tuesday, January 27th. Finally, B. Riley Financial initiated coverage on Nuvation Bio in a research note on Wednesday, November 19th. They set a “buy” rating and a $12.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Nuvation Bio currently has an average rating of “Moderate Buy” and an average price target of $11.44.

Nuvation Bio Price Performance

NUVB stock opened at $4.37 on Tuesday. Nuvation Bio has a 12-month low of $1.54 and a 12-month high of $9.75. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -7.28 and a beta of 1.50. The firm has a 50 day moving average of $6.55 and a 200-day moving average of $5.54. The company has a current ratio of 8.48, a quick ratio of 8.39 and a debt-to-equity ratio of 0.14.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 54.90%. The company had revenue of $41.87 million for the quarter, compared to the consensus estimate of $36.82 million. As a group, equities analysts expect that Nuvation Bio will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Nuvation Bio

Several institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in Nuvation Bio by 852.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after acquiring an additional 2,424,109 shares during the period. Armistice Capital LLC grew its stake in shares of Nuvation Bio by 359.2% in the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock worth $8,495,000 after purchasing an additional 1,796,000 shares in the last quarter. Capricorn Fund Managers Ltd acquired a new position in shares of Nuvation Bio during the fourth quarter valued at $14,236,000. Millennium Management LLC raised its stake in shares of Nuvation Bio by 52.4% during the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after purchasing an additional 1,298,131 shares in the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new stake in Nuvation Bio in the fourth quarter worth about $11,200,000. Institutional investors own 61.67% of the company’s stock.

Key Nuvation Bio News

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Strong commercial traction for IBTROZI: company reported 216 new patient starts in Q4 and 432 total starts since launch, and highlighted rapid adoption across treatment lines — supports revenue growth expectations and commercial momentum. PR Newswire: Q4 results & business update
• Positive Sentiment: Strategic collaboration: exclusive licensing/collaboration agreement with Eisai for taletrectinib in Europe and additional territories expands commercialization reach and derisks regional launch execution. PR Newswire: Eisai collaboration
• Positive Sentiment: Revenue beat and strong liquidity: Q4 revenue of $41.87M topped consensus (~$36.8M) and company reported $529.2M in cash, cash equivalents and marketable securities — gives runway for commercialization and R&D. Zacks: Q4 revenue beat
• Positive Sentiment: Clinical progress beyond IBTROZI: published positive Phase 2 safusidenib results showing durable responses in IDH1-mutant glioma and ongoing SIGMA protocol amendment — supports pipeline optionality. FinanzNachrichten: Q4 results & safusidenib update
• Neutral Sentiment: Earnings cadence: GAAP EPS loss of ($0.11) matched consensus (improved versus prior year loss) — meets expectations but is not an upside catalyst on its own. MarketBeat: Q4 EPS & call
• Neutral Sentiment: Management commentary & strategy: Q4 call and presentations outline first-line IBTROZI growth strategy and longer median DOR messaging — informative but will take time to convert into durable financial gains. Seeking Alpha: IBTROZI strategy
• Negative Sentiment: Analyst downgrade and target cut from UBS: UBS lowered its price target from $10 to $7 and moved to “neutral” — a direct negative signal that likely pressured the stock. Benzinga: UBS target cut
• Negative Sentiment: Profitability concerns remain: company still posts large negative net margins and negative ROE despite revenue growth — a reminder that commercial ramp must outpace costs to justify higher valuations. MarketBeat: financial metrics

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.